Possible Involvement of Muscarinic Receptor Blockade in Mirabegron Therapy for Patients with Overactive Bladder.

Abstract

The selective β 3-adrenoceptor agonist mirabegron, an established alternative to antimuscarinic therapy for patients with overactive bladder, induces additional effects against receptors, transporters, and hepatic enzymes. The present study aimed to elucidate the effects of mirabegron on muscarinic receptors in the rat bladder using radioligand binding and functional assays. Mirabegron (0.1-100 μM) inhibited specific [N-methyl-3H]scopolamine methyl chloride binding in the bladder and other tissues of rats in a concentration-dependent manner. Binding affinity in the bladder was similar to that in the heart and significantly higher than those in the submaxillary gland and brain. Mirabegron induced the concentration-dependent relaxation of carbachol-induced contractions in the rat isolated bladder. Further analyses using a two-site model revealed that the relative quantities of high- and low-affinity components for mirabegron were 44.5% and 55.5%, respectively. Respective pEC50 values were 7.06 and 4.97. Based on the receptor binding affinity and pharmacokinetics of mirabegron, muscarinic receptor occupancy in the human bladder for 24 hours after the administration of a single oral dose of 50 mg mirabegron was 37%-76%. The present results demonstrate for the first time that mirabegron may relax the detrusor smooth muscle not only by β 3-adrenoceptor activation but also muscarinic receptor blockade. SIGNIFICANCE STATEMENT: Mirabegron, the first selective β 3-adrenoceptor agonist, represents an alternative to antimuscarinic agents for management of overactive bladder (OAB). The present study aimed to clarify whether mirabegron directly binds to muscarinic receptors and affects cholinergic agonist-induced contractions in rat urinary bladder and to predict muscarinic receptor occupancy in human bladder after oral administration of mirabegron. The results demonstrated that mirabegron therapy for patients with OAB may be due not only to β 3-adrenoceptor activation but also muscarinic receptor blockade.

• Authors: Shizuo Yamada, Junko Chimoto, Mizuki Shiho, Takashi Okura, Kana Morikawa, Hirokazu Wakuda, Kazumasa Shinozuka
• Journal: The Journal of pharmacology and experimental therapeutics (J Pharmacol Exp Ther) Vol. 377 Issue 2 Pg. 201-206 (05 2021) ISSN: 1521-0103 [Electronic] United States
• PMID: 33658313 (Publication Type: Journal Article)
• Copyright: Copyright © 2021 by The American Society for Pharmacology and Experimental Therapeutics.

Chemical References

• Acetanilides
• Adrenergic beta-3 Receptor Agonists
• Muscarinic Antagonists
• Receptors, Muscarinic
• Thiazoles
• Urological Agents
• mirabegron

Topics

• Acetanilides (administration & dosage, pharmacokinetics, therapeutic use)
• Administration, Oral
• Adrenergic beta-3 Receptor Agonists (administration & dosage, pharmacology, therapeutic use)
• Animals
• Brain (metabolism)
• Male
• Muscarinic Antagonists (administration & dosage, pharmacokinetics, therapeutic use)
• Muscle Contraction
• Protein Binding
• Rats
• Rats, Sprague-Dawley
• Receptors, Muscarinic (metabolism)
• Submandibular Gland (metabolism)
• Thiazoles (administration & dosage, pharmacokinetics, therapeutic use)
• Urinary Bladder (metabolism)
• Urinary Bladder, Overactive (drug therapy)
• Urological Agents (administration & dosage, pharmacokinetics, therapeutic use)